A 52-year-old male from rural Maharashtra with no prior cardiovascular symptoms presents to a primary health centre for a routine health check-up. His BP is 148/94 mmHg, fasting blood glucose is 118 mg/dL, total cholesterol is 220 mg/dL, and BMI is 28.5 kg/m². He has a 15-year history of smoking (currently 10 cigarettes/day) and works as a farmer with minimal physical activity. Using the Indian CVD risk assessment guidelines, he is stratified as high-risk. What is the most appropriate next step in management?

Explanation

## Risk Stratification and Management Approach **Key Point:** In asymptomatic individuals stratified as high-risk by the Indian CVD risk assessment tool, the standard approach is structured counselling on lifestyle modifications as the first-line intervention, with pharmacotherapy reserved for those who fail to achieve target risk factor reduction within 3 months. ## Rationale for Correct Answer This patient meets high-risk criteria based on: - Age > 40 years - Hypertension (148/94 mmHg) - Dyslipidaemia (total cholesterol 220 mg/dL) - Impaired fasting glucose (118 mg/dL) - Active smoking - Sedentary lifestyle **High-Yield:** According to Indian guidelines (Ministry of Health & Family Welfare CVD prevention guidelines), high-risk asymptomatic individuals WITHOUT evidence of established CVD should first receive intensive lifestyle counselling. Pharmacotherapy (antihypertensives, statins) is initiated only if risk factors remain uncontrolled after 3 months of lifestyle intervention. ## Lifestyle Modification Components | Intervention | Target | Expected Benefit | |---|---|---| | Smoking cessation | Complete abstinence | ↓ CVD risk by 50% within 1 year | | Dietary modification | DASH diet, ↓ salt to <5 g/day | ↓ BP by 8–14 mmHg | | Physical activity | 150 min moderate intensity/week | ↓ BP by 5–7 mmHg, ↑ HDL | | Weight reduction | BMI target 18.5–24.9 kg/m² | ↓ BP by 5–20 mmHg per 10 kg loss | **Clinical Pearl:** A 3-month trial of lifestyle modification is cost-effective and sustainable in the Indian primary care setting, particularly in rural populations where medication adherence is often poor. This also allows time to assess true baseline risk before committing to lifelong pharmacotherapy. **Warning:** Do NOT initiate antihypertensive therapy immediately in an asymptomatic patient without first attempting lifestyle modification — this violates the stepwise risk reduction principle and increases unnecessary polypharmacy burden.